Biotech Values

[DewDiligence]

The last thing JNJ needs is to lose patent protection prematurely on a big-selling drug like Concerta. (See the bottom rows of the table in #msg-49412397 for the recent damage from JNJ’s patent expiries.)

The Concerta decision really hurts because the patent in question ran until 2018 (including the pediatric extension). Although WPI does not yet have FDA approval for its generic, the FDA will presumably approve it as soon as it replies to the outstanding Citizen Petition.